The limitations of treatment in malignant growths in the brain are too well known to need comment. In patients with cerebral metastases or astrocytomas of grade III and IV malignancy the survival period is usually to be measured in months. Conventional methods of surgery and radiotherapy have proved unsuccessful. The use of a cytotoxic drug with a selective action on the tumour cells, sparing the normal cells of the body, seems to be an ideal method of treating infiltrating and malignant tumours of the brain. Endoxana (cyclophosphamide), a nitrogen mustard derivative, was chosen because it has a relatively wider margin of safety and a lesser tendency to depression of haemopoietic tissues than many other alkylating agents. CASE 
MATERIAL
Fourteen patients, 12 with cerebral gliomas and two with cerebral metastases, admitted to Atkinson Morley's (St. George's) Hospital, were given varying courses of this drug.
All cases of malignant glioma were proven histologically, with one exception in which, though there was little doubt macroscopically about the existence of an infiltrating cystic astrocytoma, the histological examination had failed to show definite tumour tissue. Of the two cases of cerebral metastases, one was proved by burr-hole biopsy and the other had widespread metastases elsewhere.
MODE OF USE
After a complete blood count, a test dose of 100 mg. of Endoxana was given intravenously. If this did not produce any undue nausea, vomiting, or depression of the haemopoietic system, the patient was given 400 mg. of Endoxana intravenously daily. Blood counts were performed each day, a close watch being kept on the total number of leucocytes. Intravenous therapy was continued until the total white count fell to about 2,000/c.mm., and the patient was then given 50 mg. of Endoxana orally twice a day, blood counts being carried out less frequently, but usually twice or three times a week.
The dosage of oral Endoxana was varied so as to maintain a total leucocyte count of about 2,000/c.mm. Once the appropriate maintenance dose was established, the patients were discharged from hospital and treated as out- 
DISCUSSION
Because of the hazards of fractionated intra-arterial injection (Klopp, Alford, Bateman, Berry, and F. Clifford Rose, S. N. Bhagwati, and Wylie McKissock Winship. 1950) andcerebral perfusion (Woodhall etal, 1959) , it was not felt to be justified to give Endoxana by either ofthese two techniques unless it was found effective when given systemically. We, therefore, tried its systemic use in 14 cases of cerebral tumour. An earlier report (Simon, 1959) on the use of Endoxana in cerebral neoplasms stated that the drug 'was invariably well tolerated' and that if it was given 'following surgical excision, the prognosis for survival is better'. Our results do not substantiate either of these statements. The only patient surviving longer than eight months without any signs of increased intracranial pressure had had a decompressive lobectomy for an astrocytoma (grade II malignancy), and the result is comparable to the usual progress of a glioma of this grade of malignancy surgically treated. Thenecropsied specimens ofthetumour tissue have not shown any significant change which could be attributed to the Endoxana therapy. The drug is, however, safer than other alkylating agents in that the tendency to leucopenia is more easily reversible.
SUMMARY
Endoxana, a nitrogen mustard derivative, was given systemically in 14 cases of intracerebral tumour; 12 of these tumours were gliomas and two cerebral metastases.
All the patients have died from the continued growth of the tumour. Only one patient survived longer than 12 months, and in this case the tumour was histologically of low malignancy.
Side-effects included nausea, vomiting, marked alopecia, iron-deficiency anaemia, and severe leucopenia; the last disappeared when the drug was discontinued. In one case, transient obstructive jaundice occurred.
In this series the systemic administration of Endoxana had no therapeutic effect.
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